2010 New Antimicrobial Drug Discovery and Development Gordon Research Conference

描述（由申请人提供）：本次戈登会议旨在解决一个严重的国家和国际问题：缺乏新的抗微生物药物治疗多重耐药感染。在重症监护室（ICU）和社区中，通常导致严重感染的生物体已经对我们许多最有效的抗生素产生耐药性。在共同体中，肺炎链球菌等微生物对内酰胺类抗生素的不敏感率超过20%。其他有效的药物，如大环内酯类，具有约40%的耐药率。社区获得性MRSA在美国各地的流行率呈爆炸式增长，在急诊科很常见。在ICU中，MRSA占所有金黄色葡萄球菌感染的大约50%，并且我们已经看到多重耐药革兰氏阴性生物体的出现，使得即使是常见的病原体如克雷伯氏菌和大肠杆菌也不能被感染。大肠杆菌可能携带超广谱β-内酰胺酶，使它们对我们的许多最好的药物产生耐药性，在K-pc酶的情况下，这种耐药性包括碳青霉烯类。在铜绿假单胞菌和不动杆菌属的情况下，现在感染病原体对所有许可的抗生素都具有耐药性是相当常见的。我们绝望的一个衡量标准是，我们已经复活了50年前相对有毒的药物（粘菌素/多粘菌素），以便至少有一种可用的治疗干预措施。 在这次会议上，我们有一个独特的跨学科的方法来解决这个问题，化学家，基础生物学家和转化科学家会面，工业，学术界，监管机构和政治观察员都是利益相关者，并被邀请为交流做出贡献。我们过去的会议在科学上是严格和开放的，新的科学不断涌现，确定这一过程中的瓶颈也是这一过程的一部分。 我们有一个会议，我们致力于最广泛的参与，特别是，希望在博士后水平的领域的年轻成员的包容性，带来新的视角正在审查的问题。该网站非常适合这种交流，会议的结构遵循经典的戈登会议格式。选择讨论领导者的目的是在演讲后进行强有力的、有见地的讨论。会议的形式是民主的，这样所有的声音都会被听到，重点将是展示最好和最新的科学，并提出正确的问题，以推动该领域的发展。在这项建议中，我们要求为这项重要工作提供补充支持。

DESCRIPTION (provided by applicant): This Gordon Conference is aimed at a serious national and international problem: the lack of new antimicrobial agents for multi-resistant infections. In both the Intensive Care Unit (ICU) and the Community, organisms that commonly cause serious infections have become resistant to many of our most effective antibiotics. In the Community, organisms such as Streptococcus pneumonia have a rate of non- susceptibility to ¿-lactam antibiotics exceeding 20%. Other effective agents, such as macrolides, have resistance rates on the order of 40%. Community-Acquired MRSA has exploded in prevalence across the United States and is commonly seen in Emergency Departments. In the ICU, MRSA makes up approximately 50% of all Staphylococcus aureus infections and we have seen the advent of multi- resistant Gram-negative organisms, so that even common pathogens such as Klebsiella and E. coli may carry extended-spectrum ¿-lactamases, rendering them resistant to many of our best agents and, in the case of K-pc enzymes, this resistance profile includes carbapenems. In the case of Pseudomonas aeruginosa and Acinetobacter species, it is now reasonably common for an infecting pathogen to be resistant to all licensed antibiotics. A measure of our desperation is that we have resurrected 50 year-old, relatively toxic agents (colistin/polymixins) to have at least one available therapeutic intervention. In this Conference, we have a unique cross-disciplinary approach to the problem, where chemists, basic biologists and translational scientists meet and where Industry, Academia, Regulatory Agencies and political observers are all stakeholders and are invited to contribute to the interchange. Our past meetings have been scientifically rigorous and open, with both new science coming forward and the identification of bottlenecks in the process being part of the process. We have a conference where we are dedicated to the broadest participation and, in specific, are desirous of inclusion of younger members of the field at the post-doctoral level, to bring fresh perspective to the problems being examined. The site is well-suited for this interchange and the structure of the Conference follows the classical Gordon Conference format. The Discussion Leaders have been chosen with an eye toward generating robust, insightful discussion after the presentations. The format is democratic so that all voices will be heard and the emphasis will be on presenting the best and newest science and asking the correct questions to push the field forward. In this proposal, we ask for supplementary support for this important undertaking.